Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study

Página do item simplificado
dc.citation.volume55
dc.contributor.authorPerazzio, Aline S. B. [UNIFESP]
dc.contributor.authorOliveira, Jose Salvador R. [UNIFESP]
dc.contributor.authorFigueiredo, Vera L. P.
dc.contributor.authorChauffaille, Maria de Lourdes L. F. [UNIFESP]
dc.coverageOxford
dc.date.accessioned2020-07-17T14:02:26Z
dc.date.available2020-07-17T14:02:26Z
dc.date.issued2017
dc.description.abstractStudies have demonstrated that abnormalities in interferon regulatory factor-1 (IRF-1) expression might develop myelodysplastic syndromes (MDS). IRF-1 was described as modulator of T regulatory (Treg) cells by suppressing Foxp3 on mice. We aimed to determine the role of Treg and IRF-1 in MDS. Thirty-eight MDS patients fulfilling WHO criteria and classified according to risk scores were evaluated at time 0 (TO) and after 12 months (T12) for: Treg suppression activity in coculture with T effector (Teff) cellsen
dc.description.abstractIRF-1 and Foxp3 genetic expression by qRT-PCRen
dc.description.abstractIL-2, 4, 6, 10, 17, TNF alpha. and IFN gamma production by Cytometric Bead Array. No differences in Foxp3 expression (T0 = 0.06 +/- 0.06 vs T12 = 0.06 +/- 0.12, p = 0.5), Treg number (TO = 5.62 +/- 2.84 x 10(5) vs T12 =4.87 +/- 2.62 x 10(5)en
dc.description.abstractp = 0.3) and Teff percentage (T0=16.8 +/- 9.56% vs T12 =13.1 +/- 6.3%en
dc.description.abstractp = 0.06) were observed on T12. Low risk MDS patients showed a higher number of Treg (5.2 +/- 2.6 x 10(5)) versus high risk group (2.6 +/- 1.2 x 10(5), p = 0.03). Treg suppression activity was impaired on TO and T12.Cytokine production and IRF-1 expression were increased on T12. The correlation between IRF-1 and FoxP3 was negative (r(2) = 0.317, p = 0.045) on T0. These results suggest a hyper activity of the immune system, probably secondary to Treg suppression activity impairment. This state may induce the loss of tolerance culminating in the proliferation of MDS clones. (C) 2017 Elsevier Ltd. All rights reserved.en
dc.description.affiliationUniv Fed Sao Paulo, Div Hematol, Sao Paulo, SP, Brazil
dc.description.affiliationFleury Grp, Res & Dev, Sao Paulo, SP, Brazil
dc.description.affiliationHosp Santa Marcelina, Div Hematol, Sao Paulo, SP, Brazil
dc.description.affiliationInst Assistencia Med Servidor Publ Estanbul, Div Hematol, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Hematol, Sao Paulo, SP, Brazi
dc.description.sourceWeb of Science
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/50910-8]
dc.description.sponsorshipResearch and Development from Fleury Group [001/2012]
dc.format.extent6-17
dc.identifierhttp://dx.doi.org/10.1016/j.leukres.2017.01.008
dc.identifier.citationLeukemia Research. Oxford, v. 55, p. 6-17, 2017.
dc.identifier.doi10.1016/j.leukres.2017.01.008
dc.identifier.issn0145-2126
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54808
dc.identifier.wosWOS:000397846500002
dc.language.isoeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relation.ispartofLeukemia Research
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectIRF-1en
dc.subjectTregen
dc.subjectMyelodysplastic syndromeen
dc.subjectT regulatory cellsen
dc.subjectFoxp3en
dc.subjectImmune systemen
dc.titleIncrease of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos